Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) are currently rated with a consensus “Buy” recommendation by eleven brokerage firms covering the company, according to MarketBeat.com. Among these analysts, one has issued a sell rating, eight have given a buy rating, and two have assigned a strong buy rating.
The average price target from these analysts stands at $21.10 per share, reflecting their outlook on the company’s potential performance in the market.
**Why this matters**
Analyst recommendations and price targets provide investors with insights into market sentiment and expectations for a stock’s future value. The predominantly positive ratings for Trevi Therapeutics suggest confidence in the company’s prospects, which may influence investor decisions.
Source: NewsData